Negotiation outcomes from the Cell and Gene Therapy Access Model reveal important insights for healthcare policy.
Lessons from the first negotiation cycle can enhance future models for access to cell and gene therapies.
The viewpoint addresses the implications for both Medicare and Medicaid in the context of emerging therapies.
Understanding these lessons is critical for improving healthcare accessibility and funding for innovative treatments.
Abstract
This Viewpoint discusses lessons learned from the first negotiation cycle of the Centers for Medicare amp; Medicaid Services’ Cell and Gene Therapy Access Model.